Lung Cancer Clinical Trial
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
Summary
VAPOR-C is a randomised study of the impact of IV versus inhaled anaesthesia (propofol versus sevoflurane) and lidocaine versus no lidocaine on duration of disease free survival inpatients with either colorectal or non small cell lung cancer.
Full Description
VAPOR-C is a pragmatic, event-driven, randomised controlled trial, with a single blind 2x2 factorial design for sevoflurane/propofol and for intravenous lidocaine infusion / no lidocaine infusion.
This trial is designed to test for superiority in disease free survival (DFS) of propofol (total intravenous anaesthesia -TIVA) over sevoflurane (inhalational volatile anaesthesia) and intravenous lidocaine over no lidocaine in patients undergoing surgery for colorectal or non small cell lung cancer (NSCLC). The combination of two cancer types will help address the need to demonstrate the effects of anaesthetic technique across cancers to inform generalisable anaesthesia guidelines. Both NSCLC and colorectal cancer are important for this study due to high incidence rate, many longer-term survivors, and importantly the high risk of local or distant recurrence despite complete surgical resection. In addition, the study will collect additional data in a nested cohort related to the exploratory objectives.
The study aims to recruit 3,500 patients in Australia, New Zealand, Canada, United States and Europe.
Eligibility Criteria
Inclusion Criteria:
Male or female patients aged 18 years or older at screening
Has provided written informed consent for the trial
Patient with American Joint committee on Cancer (AJCC) 8th edition Stage I-III colorectal cancer or Stage I-IIIa NSCLC, as confirmed by histological or cytological diagnosis. In cases where a histological diagnosis is not possible, suspected diagnosis through imaging techniques is acceptable.
Patient has an American Society of Anaesthesiologists (ASA) score of 1 to 3
Scheduled to receive elective, surgical resection with curative intent
Surgery expected to last ≥2 hours and expected to require ≥2 nights hospital stay
Able to comply with protocol requirements and follow-up procedures
Exclusion Criteria:
Confirmed or suspected allergy to propofol, sevoflurane or intravenous lidocaine
Patient with significant liver disease (with elevated International Normalised Ratio (INR) or bilirubin and/or low albumin; i.e. Childs-Pugh Score >Class A;
Patient at personal or familial risk of malignant hyperthermia or porphyria
Patient with a history of other malignancies within the past 5 years. However, patients with malignancies managed with curative therapy and considered to be at low risk of recurrence such as treated skin basal cell carcinoma, squamous cell carcinoma, malignant melanoma ≤1.0mm without ulceration, localised thyroid cancer, cervical carcinoma in situ or prior malignancies with high likelihood of cure (e.g. low grade prostate and breast cancer) may be included in the study
Patient has distant metastases
Patient with an actual body weight less than 45kg
Patients taking the following drugs that are moderate-strong inhibitors of the CYP1A2 and CYP3A4 metabolic pathways within 72 hours prior to surgery: Antibiotics - 'mycin' class: Clarithromycin, Telithromycin, Azithromycin, Erythromycin Antibiotics - 'floxacin' class Ciprofloxacin (exception: can be used preoperatively within a bowel prep regime), Norfloxacin, Levofloxacin, Sparfloxacin Antibiotics - other: Chloramphenicol, Isoniazid Antifungals: Fluconazole, Itraconazole, Ketoconazole, Posaconazole, Voriconazole Antiretrovirals: Atazanavir; Darunavir; Indinavir; Lopinavir; Nelfinavir; Ombitasvir, Paritaprevir, Ritonavir and Saquinavir. Antidepressants/ADHD: Fluvoxamine, Enoxacine. Calcium-channel blockers: Diltiazem, Verapamil Monoclonal Antibodies: Ceritinib, Idelalisib, Lonafarnib, Tucatinib. Other strong cytochrome P450 3A4 inhibitors: Cimetidine, Cobicistat; grapefruit juice, Mifepristone, Nefazodone.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 26 Locations for this study
Pittsburgh Pennsylvania, 15213, United States More Info
Contact
Houston Texas, 77030, United States More Info
Contact
Camperdown New South Wales, 2050, Australia More Info
Contact
Camperdown New South Wales, 2050, Australia More Info
Contact
Randwick New South Wales, 2031, Australia More Info
Contact
Herston Queensland, 4029, Australia More Info
Contact
Southport Queensland, 4215, Australia More Info
Contact
Woolloongabba Queensland, 4102, Australia More Info
Contact
Ballarat Central Victoria, 3350, Australia More Info
Contact
Fitzroy Victoria, 3065, Australia More Info
Contact
Footscray Victoria, 3011, Australia More Info
Contact
How clear is this clinincal trial information?